IN UTERO MODEL TO ASSESS FATE OF TRANSPLANTED CELLS FOR PEDIATRIC THERAPIES

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 研究表明，对被诊断为遗传性疾病的婴儿进行早期治疗可以提供最佳的存活率和临床结果，而未成熟的细胞来源可能是最有效的移植方法。这些研究探索从两个不同来源移植的人类细胞的命运，并通过解决与临床移植的人类多能细胞相关的基本问题来克服瓶颈。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Studies suggest that early treatment of infants diagnosed with an inherited disease provides the best survival and clinical outcomes, and that immature cell sources may be most efficient for transplant. These studies explore the fate of transplanted human cells from two differing sources and focus on overcoming bottlenecks by addressing essential issues related to human pluripotent cells for clinical transplantation.